What changed from existing technology?
This study shows that proteins in tiny particles in the blood can affect how well treatments targeting a protein called CLDN18.2 work against stomach and intestinal cancers.
This is the first study to show that extracellular vesicle proteins can both monitor and interfere with CLDN18.2-targeted therapies, revealing a new mechanism of treatment resistance.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
geted therapies. By profiling serial plasma samples of patients from the CT041-CG4006 trial (CLDN18.2- CAR-T-therapy) or the GLOW trial (Zolbetuximab), we ide
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
These findings suggest that monitoring EV proteins could help predict treatment response and guide therapeutic strategies for CLDN18.2-targeted therapies in gastrointestinal cancers.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.